1 -Antitrypsin deficiency and neonatal hepatitis

Area of Science:

• Hepatology
• Genetics
• Pediatrics

Background:

• Neonatal hepatitis is a significant cause of liver disease in infants.
• Alpha-1-antitrypsin deficiency (A1ATD) is a genetic disorder that can affect the liver.
• The association between A1ATD and neonatal hepatitis requires further investigation.

Purpose of the Study:

• To investigate the prevalence of alpha-1-antitrypsin deficiency in infants with neonatal hepatitis.
• To explore the clinical and pathological spectrum of liver disease in infants with A1ATD.
• To examine the role of Australia antigen (Hepatitis B surface antigen) in the pathogenesis of neonatal hepatitis in A1ATD patients.

Main Methods:

• Regional survey of neonatal hepatitis cases.
• Genetic testing for alpha-1-antitrypsin phenotype (ZZ phenotype).
• Clinical assessment, liver function tests, and liver biopsy analysis.
• Serological testing for Australia antigen and antibodies.

Main Results:

• Five out of 28 infants (17.8%) with neonatal hepatitis had alpha-1-antitrypsin deficiency (ZZ phenotype).
• Clinical presentations ranged from acute hepatitis-like illness to minimal liver function abnormalities.
• Cirrhosis developed in three infants, while two showed milder liver damage.
• Australia antigen was detected in three infants and in parents of another case.
• Hepatitis B virus (Australia antigen) was present in infants with A1ATD and neonatal hepatitis.

Conclusions:

• Alpha-1-antitrypsin deficiency may be a more common underlying factor in neonatal hepatitis than previously recognized.
• Australia antigen may act as a crucial trigger, exacerbating liver injury in infants with A1ATD.
• Early diagnosis and management of A1ATD are essential for affected infants.